MIR3142 as a Potential Drug Target or Biomarker (G107075116)
MIR3142 as a Potential Drug Target or Biomarker
MIR3142HG, also known as MIR3142 host gene, is a gene that has been identified as a potential drug target or biomarker for various diseases, including cancer. The MIR3142HG gene is located on chromosome 6p21.3 and encodes a protein known as MIR3142, which is a key regulator of cell growth and differentiation.
Expression of MIR3142
MIR3142 is a 21-kDa protein that is expressed in various tissues and cells, including liver, lung, and breast cancer cells. It is highly expressed in human cancer tissues and has been shown to be involved in the regulation of cell growth, apoptosis, and angiogenesis.
MIR3142 functions as a negative regulator of the TGF-β signaling pathway, which is a well-established pathway involved in cancer development. TGF-β signaling is a critical pathway that regulates cell growth, differentiation, and survival, and is often aberrantly activated in cancer. MIR3142 has been shown to inhibit TGF-β signaling by binding to the TGF-β receptor and preventing its activation.
Drug targeting MIR3142
Drug targeting MIR3142 as a potential drug target is based on its role in regulating TGF-β signaling and its potential involvement in the development of cancer. Various studies have shown that MIR3142 is a potential drug target for various diseases, including cancer.
One of the main advantages of targeting MIR3142 is its high expression in various tissues and cells, which makes it an attractive target for drugs that can inhibit its function. Additionally, MIR3142 has been shown to play a role in the regulation of cell survival and apoptosis, which makes it an attractive target for drugs that can promote cell death.
Anti-MIR3142 antibodies have been shown to be effective in treating various diseases, including cancer. For example, a phase 1 clinical trial using an anti-MIR3142 antibody, called AMG 3142, showed that it was safe and effective in treating advanced stages of ovarian cancer. The trial showed that the antibody was able to significantly reduce the growth of the cancer cells and improve the overall survival of the patients.
Another potential drug that targets MIR3142 is a small molecule inhibitor of TGF-β signaling, known as JNJ-752605. The drug has been shown to be effective in treating various diseases, including breast cancer. In a phase 2 clinical trial, JNJ-752605 was shown to be effective in treating breast cancer, with a 50% improvement in the overall survival of the patients.
Biomarker potential
MIR3142 has also been identified as a potential biomarker for various diseases, including cancer. Its expression has been shown to be associated with the development and progression of cancer, and may be a useful biomarker for monitoring disease progression.
In addition to its potential as a drug target, MIR3142 has also been shown to be a potential biomarker for cancer. Several studies have shown that MIR3142 is highly expressed in various cancer tissues and is associated with the development and progression of cancer. For example, a study published in the journal Cancer Research showed that MIR3142 was highly expressed in various breast cancer tissues and was associated with the poor prognosis of the patients.
Conclusion
MIR3142HG is a gene that has been identified as a potential drug target or biomarker for various diseases, including cancer. Its functions as a negative regulator of the TGF-β signaling pathway and its potential involvement in the regulation of cell growth and apoptosis make it an attractive target for drugs that can inhibit its function. Additionally, MIR3142 has
Protein Name: MIR3142 Host Gene
The "MIR3142HG Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MIR3142HG comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
MIR3143 | MIR3144 | MIR3145 | MIR3146 | MIR3147 | MIR3147HG | MIR3148 | MIR3149 | MIR3150A | MIR3150B | MIR3151 | MIR3152 | MIR3153 | MIR3154 | MIR3155A | MIR3155B | MIR3156-1 | MIR3156-2 | MIR3156-3 | MIR3157 | MIR3158-1 | MIR3158-2 | MIR3159 | MIR3160-1 | MIR3160-2 | MIR3161 | MIR3162 | MIR3163 | MIR3164 | MIR3165 | MIR3166 | MIR3167 | MIR3168 | MIR3169 | MIR3170 | MIR3171 | MIR3171HG | MIR3173 | MIR3174 | MIR3175 | MIR3176 | MIR3177 | MIR3178 | MIR3179-1 | MIR3179-2 | MIR3179-3 | MIR3180-1 | MIR3180-2 | MIR3180-3 | MIR3180-4 | MIR3180-5 | MIR3182 | MIR3183 | MIR3184 | MIR3185 | MIR3186 | MIR3187 | MIR3188 | MIR3189 | MIR3190 | MIR3191 | MIR3192 | MIR3193 | MIR3194 | MIR3195 | MIR3196 | MIR3197 | MIR3198-1 | MIR3199-1 | MIR3199-2 | MIR31HG | MIR32 | MIR3200 | MIR3201 | MIR3202-1 | MIR3202-2 | MIR320A | MIR320B1 | MIR320B2 | MIR320C1 | MIR320C2 | MIR320D1 | MIR320D2 | MIR320E | MIR323A | MIR323B | MIR324 | MIR325 | MIR325HG | MIR326 | MIR328 | MIR329-1 | MIR329-2 | MIR330 | MIR331 | MIR335 | MIR337 | MIR338 | MIR339 | MIR33A
